Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2021-08-16 Report Publication Anno…
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
DATE OF BOARD MEETING
Report Publication Announcement Classification · 95% confidence The document is an announcement from the Board of Directors of CStone Pharmaceuticals about the date of a board meeting to consider and approve the interim results for the six months ended June 30, 2021, and the possible payment of an interim dividend. The document does not contain any actual financial data or the interim results themselves, but only announces the upcoming meeting where these will be considered and published. The document length is short (1555 characters) and it is clearly an announcement rather than the report itself. According to the 'MENU VS MEAL' rule, this is a Report Publication Announcement (RPA) type document, as it announces the timing of the report publication rather than providing the report or financial data itself.
2021-08-16 English
NOTIFICATION OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from Yanzhou Coal Mining Company Limited notifying the market of an upcoming board meeting scheduled for 27 August 2021. The purpose of the meeting includes considering the publication of the unaudited interim results for the six months ended 30 June 2021. The document does not contain any financial data or results itself, but merely informs about the meeting and the intention to publish interim results. The length is only 1473 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the MENU VS MEAL RULE, this is an announcement about a report (interim results) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2021-08-13 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2021-08-11 English
ANNOUNCEMENT ON RESULTS OF THE ISSUANCE OF THE 2021 THIRD TRANCHE OF SUPER-SHORT-TERM BONDS
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the results of a bond issuance by Yanzhou Coal Mining Company Limited. It details the issuance amount, interest rate, term, and other key terms of the super-short-term bonds. The document is relatively short (3005 characters) and serves as a formal announcement of a financing activity rather than a full financial report or detailed analysis. It references regulatory rules and provides issuance details but does not contain comprehensive financial statements or management discussion. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2021-08-11 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2021
Share Issue/Capital Change Classification · 100% confidence The document is a detailed monthly report on movements in securities, specifically focusing on authorized and issued shares, share options, and confirmations related to share capital changes for CStone Pharmaceuticals. It includes data on share capital, share options exercised, and confirmations by a company director. The document is submitted to the Hong Kong Exchanges and Clearing Limited and references compliance with listing rules. It is not a full financial report, earnings release, or management discussion, but rather a regulatory disclosure about share capital movements and share issuance. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues and capital changes. The document length and detail confirm it is the report itself, not just an announcement of a report publication or a certification letter, so it is not RPA or RNS.
2021-08-05 English
VOLUNTARY ANNOUNCEMENT - CSTONE'S PARTNER SERVIER ANNOUNCED POSITIVE TOPLINE DATA FROM THE GLOBAL PHASE III STUDY OF TIBSOVO (IVOSIDENIB TABLETS) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding positive topline data from a Phase III clinical trial (AGILE study) of a drug (TIBSOVO) in combination with azacitidine for AML patients. It discusses clinical trial results, safety profile, and regulatory status including FDA and NMPA submissions. There are no financial statements, detailed financial performance data, or comprehensive management discussion of financial results. The document is not a full annual or interim report, nor is it an earnings release or investor presentation. It is a corporate announcement about clinical trial results and regulatory progress, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other specific categories.
2021-08-04 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.